Section 1 of 6
Terms and abbreviations
1 evidence topic · 0 sources
| Abbreviation | Term |
|---|---|
| AE | Adverse event |
| AHFS | American Hospital Formulary Service |
| AXL | AXL receptor tyrosine kinase |
| BRAF | B-Raf proto-oncogene |
| CI | Confidence interval |
| CR | Complete response |
| CRC | Colorectal cancer |
| DCR | Disease-control rate |
| DLT | Dose-limiting toxicity |
| dMMR | Deficient mismatch repair |
| ECOG | Eastern Cooperative Oncology Group |
| EGFR | Epidermal growth factor receptor |
| EORTC | European Organisation for Research and Treatment of Cancer |
| EQ-5D-5L | EuroQol five-dimension, five-level instrument |
| ER | Emergency room |
| FDA | Food and Drug Administration |
| FOLFIRI | Folinic acid, fluorouracil, and irinotecan |
| FOLFOX | Folinic acid, fluorouracil, and oxaliplatin |
| HAIC | Hepatic arterial infusion chemotherapy |
| HER2 | Human epidermal growth factor receptor 2 |
| HR | Hazard ratio |
| HRQoL | Health-related quality of life |
| HTA | Health technology assessment |
| ICER | Incremental cost-effectiveness ratio |
| ICI | Immune checkpoint inhibitor |
| ICU | Intensive care unit |
| ITT | Intention-to-treat |
| IV | Intravenous |
| KRAS | KRAS proto-oncogene |
| LM | Liver metastases |
| mCRC | Metastatic colorectal cancer |
| MER | MER receptor tyrosine kinase |
| MET | MET receptor tyrosine kinase |
| MFH | Major financial hardship |
| MMR | Mismatch repair |
| MSI | Microsatellite instability |
| MSI-H | Microsatellite instability-high |
| MSS | Microsatellite stable |
| MTD | Maximum tolerated dose |
| NDA | New Drug Application |
| NLM | Non-liver metastases |
| nlmITT | Non-liver metastases intention-to-treat |
| NRAS | NRAS proto-oncogene |
| NTRK | Neurotrophic tyrosine receptor kinase |
| ORR | Objective response rate |
| OS | Overall survival |
| PD-1 | Programmed cell death protein 1 |
| PD-L1 | Programmed death ligand 1 |
| PFS | Progression-free survival |
| PK | Pharmacokinetics |
| pMMR | Proficient mismatch repair |
| PO | Oral administration |
| PR | Partial response |
| PS | Performance status |
| Q3W | Every three weeks |
| Q4W | Every four weeks |
| QALY | Quality-adjusted life-year |
| QD | Once daily |
| QLQ-C30 | Quality of Life Questionnaire Core 30 |
| QLQ-CR29 | Quality of Life Questionnaire colorectal module |
| QoL | Quality of life |
| RAS | RAS family of proto-oncogenes |
| RD | Recommended dose |
| RECIST | Response Evaluation Criteria in Solid Tumors |
| RTK | Receptor tyrosine kinase |
| SBRT | Stereotactic body radiotherapy |
| SD | Stable disease |
| SIRT | Selective internal radiotherapy |
| SOC | Standard of care |
| TA | Thermal ablation |
| TACE | Transarterial chemoembolisation |
| TAM | TYRO3, AXL, and MER receptor tyrosine kinases |
| TARE | Transarterial radioembolisation |
| TEADA | Treatment-emergent antidrug antibody |
| TKI | Tyrosine kinase inhibitor |
| VEGF | Vascular endothelial growth factor |
| VEGFR | Vascular endothelial growth factor receptor |